Taysha Gene Therapies, Inc.
NASDAQ:TSHABiotechnology
+$0.10 today
- Market cap
- $1.30B
- Beta
- 1.18
- P/E (TTM)
- -17.7
- EPS (TTM)
- -$0.35
Volume 3.38M
Average 2.73M
TSHA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Taysha Gene Therapies, Inc.NASDAQ: TSHA
Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Free cash flow growth accelerates
Q2 FY2026 free cash flow of $40.42M (cash outflow) rose 100.3% year over year, ahead of the +64.3% change in trailing-twelve-month free cash flow. Sequentially, it fell 7.9% from the prior quarter. Over 3 fiscal years it compounded at -6.1% a year.
Context
- Free cash flow amounted to 960.1% of revenue in FY2025, down 19.2 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +100.3% holds above the trailing-twelve-month pace of +64.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (93.83M) USD
- Year-over-year change
- -15.0%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (93.83M) | -15.0% |
| FY2024 | 2024-12-31 | (81.6M) | -1.5% |
| FY2023 | 2023-12-31 | (80.39M) | +29.0% |
| FY2022 | 2022-12-31 | (113.26M) | +18.3% |
| FY2021 | 2021-12-31 | (138.6M) | — |
Free Cash Flow vs competitors
How TSHA compares with its peers on the latest reported figures
- TSHA's LTM Jun 2026 free cash flow of $135.57M is the 3rd largest of the 9 companies compared; the peer median is $107.59M.
- Its year-over-year change of +64.3% is the 3rd highest of 9, against a peer median of +15.0%.
- Free cash flow amounts to 2471.7% of revenue for TSHA, versus a peer median of 269.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $236.4M | +171.9% | -19.0% | 269.2% | |
| LTM Mar 2026 | $179.8M | -15.6% | +0.7% | — | |
| LTM Jun 2026 | $135.57M | +64.3% | -6.1% | 2471.7% | |
| LTM Mar 2026 | $130.06M | -17.1% | +3.6% | 147.4% | |
| LTM Mar 2026 | $129.94M | +14.0% | +108.0% | 356.1% | |
| LTM Mar 2026 | $106.14M | +115.2% | -4.9% | 4.9% | |
| LTM Mar 2026 | $85.24M | +35.3% | +24.6% | 586.2% | |
| LTM Mar 2026 | $82.61M | +15.9% | +12.5% | — | |
| LTM Mar 2026 | $20.59M | +10.2% | +14.1% | — | |
| Peer median (excluding TSHA) | $107.59M | +15.0% | +8.0% | 269.2% | |
Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (174.52M) | (166.01M) | (111.57M) | (89.3M) | (109M) |
| Depreciation & Amortization | 492K | 1.17M | 1.37M | 1.25M | 1.15M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 18.18M | 18.04M | 7.91M | 13.1M | 13.3M |
| Change in Working Capital | 28.67M | 18.52M | (18.01M) | (12.47M) | (5.37M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 14.49M | (7.8M) | (2.3M) | (2.92M) | (153K) |
| Other Working Capital | 14.17M | 26.32M | (15.72M) | (9.55M) | (5.22M) |
| Other Non-Cash Items | 10.14M | 39.89M | 47.28M | 6.19M | 6.83M |
| Operating Cash Flow | (117.04M) | (88.39M) | (73.02M) | (81.23M) | (93.09M) |
| Capital Expenditures | (21.55M) | (24.87M) | (7.37M) | (374K) | (738K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (6.25M) | (61K) | (3.48M) | 11K | 134K |
| Investing Cash Flow | (21.55M) | (24.93M) | (7.35M) | (363K) | (604K) |
| Debt Repayment | 39.96M | 0 | (3.45M) | 0 | 9.24M |
| Common Stock Issued | (360K) | 53.24M | 140.79M | 76.78M | 265.69M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (514K) | (1.15M) | (947K) | (96K) | (337K) |
| Financing Cash Flow | 39.08M | 52.1M | 136.39M | 76.68M | 274.59M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (99.51M) | (61.22M) | 56.02M | (4.9M) | 180.9M |
| Free Cash Flow | (138.6M) | (113.26M) | (80.39M) | (81.6M) | (93.83M) |
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
Intrinsic Alpha fair value
Locked
Current Price
$3.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.